Commercial prospects for genomic sequencing technologies

Nature Reviews Drug Discovery

Volumn 12, Issue 5, 2013, Pages 341-342

  Mohamed, Sharmarke ^a   Syed, Basharut A ^a  

^a Visiongain Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CLOPIDOGREL; DASATINIB; DNA POLYMERASE; IMATINIB; IRINOTECAN; MARAVIROC; MERCAPTOPURINE; NILOTINIB; TRASTUZUMAB; WARFARIN;

ARTICLE; BREAST CANCER; CEREBROVASCULAR ACCIDENT; CHRONIC MYELOID LEUKEMIA; COLON CANCER; EXOME; GASTROINTESTINAL STROMAL TUMOR; GENE SEQUENCE; GENOME ANALYSIS; HEART INFARCTION; HUMAN GENOME PROJECT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHATIC LEUKEMIA; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOEMBOLISM; TRANSLATIONAL RESEARCH;

GENOMICS; HEALTH CARE SECTOR; PHARMACOGENETICS; SEQUENCE ANALYSIS;

EID: 84877268066     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4006     Document Type: Article

References (3)

1. Visiongain. Genomic sequencing technologies for medicine: market prospects 2011-2021. Visiongain (2011).
2. Shendure, J. & Lieberman Aiden, E. The expanding scope of DNA sequencing. Nature Biotech. 30, 1084-1094 (2012).
3. Norman, T. et al. The precompetitive space: time to move the yardsticks. Sci. Transl. Med. 3, 76cm10 (2011).